Bv8 regulates myeloid-cell-dependent tumour angiogenesis

被引:525
作者
Shojaei, Farbod [1 ]
Wu, Xiumin [1 ]
Zhong, Cuiling [1 ]
Yu, Lanlan [1 ]
Liang, Xiao-Huan [1 ]
Yao, Jenny [1 ]
Blanchard, Dominique [1 ]
Bais, Carlos [1 ]
Peale, Franklin V. [1 ]
van Bruggen, Nicholas [1 ]
Ho, Calvin [1 ]
Ross, Jed [1 ]
Tan, Martha [1 ]
Carano, Richard A. D. [1 ]
Meng, Y. Gloria [1 ]
Ferrara, Napoleone [1 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
关键词
D O I
10.1038/nature06348
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bone- marrow- derived cells facilitate tumour angiogenesis, but the molecular mechanisms of this facilitation are incompletely understood. We have previously shown that the related EG- VEGF and Bv8 proteins, also known as prokineticin 1 ( Prok1) and prokineticin 2 ( Prok2), promote both tissue- specific angiogenesis and haematopoietic cell mobilization. Unlike EG- VEGF, Bv8 is expressed in the bone marrow. Here we show that implantation of tumour cells in mice resulted in upregulation of Bv8 in CD11b(+) Gr1(+) myeloid cells. We identified granulocyte colony- stimulating factor as a major positive regulator of Bv8 expression. Anti- Bv8 antibodies reduced CD11b(+) Gr1(+) cell mobilization elicited by granulocyte colony- stimulating factor. Adenoviral delivery of Bv8 into tumours was shown to promote angiogenesis. Anti- Bv8 antibodies inhibited growth of several tumours in mice and suppressed angiogenesis. Anti- Bv8 treatment also reduced CD11b(+) Gr1(+) cells, both in peripheral blood and in tumours. The effects of anti- Bv8 antibodies were additive to those of anti- Vegf antibodies or cytotoxic chemotherapy. Thus, Bv8 modulates mobilization of CD11b(+) Gr1(+) cells from the bone marrow during tumour development and also promotes angiogenesis locally.
引用
收藏
页码:825 / U6
页数:10
相关论文
共 45 条
[1]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[2]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[3]   Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus [J].
Cheng, MY ;
Bullock, CM ;
Li, CY ;
Lee, AG ;
Bermak, JC ;
Belluzzi, J ;
Weaver, DR ;
Leslie, FM ;
Zhou, QY .
NATURE, 2002, 417 (6887) :405-410
[4]   Regulation of neutrophil homeostasis [J].
Christopher, Matthew J. ;
Link, Daniel C. .
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (01) :3-8
[5]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[6]   Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBP ratio and granulocyte colony-stimulating factor [J].
Dahl, R ;
Walsh, JC ;
Lancki, D ;
Laslo, P ;
Iyer, SR ;
Singh, H ;
Simon, MC .
NATURE IMMUNOLOGY, 2003, 4 (10) :1029-1036
[7]   Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells [J].
De Palma, M ;
Venneri, MA ;
Roca, C ;
Naldini, L .
NATURE MEDICINE, 2003, 9 (06) :789-795
[8]   Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors [J].
De Palma, M ;
Venneri, MA ;
Galli, R ;
Sergi, LS ;
Politi, LS ;
Sampaolesi, M ;
Naldini, L .
CANCER CELL, 2005, 8 (03) :211-226
[9]   VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis [J].
Dong, JY ;
Grunstein, J ;
Tejada, M ;
Peale, F ;
Frantz, G ;
Liang, WC ;
Bai, W ;
Yu, LL ;
Kowalski, J ;
Liang, XH ;
Fuh, G ;
Gerber, HP ;
Ferrara, N .
EMBO JOURNAL, 2004, 23 (14) :2800-2810
[10]   PK1/EG-VEGF induces monocyte differentiation and activation [J].
Dorsch, M ;
Qiu, YB ;
Soler, D ;
Frank, N ;
Duong, T ;
Goodearl, A ;
O'Neil, S ;
Lora, J ;
Fraser, CC .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 78 (02) :426-434